Welcome to our dedicated page for SELECT MEDICAL HOLDINGS SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SELECT MEDICAL HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SELECT MEDICAL HOLDINGS's regulatory disclosures and financial reporting.
Select Medical Holdings director Thomas Scully disposed of his remaining shares as part of a cash merger. The Form 4 shows a disposition of 103,424 shares of common stock to the issuer at $16.50 per share, leaving him with zero shares directly held after the transaction.
According to the merger agreement, each share of common stock, including unvested restricted shares that vested immediately before closing, was converted into the right to receive $16.50 in cash, less applicable tax withholdings. This reflects the automatic cash-out of his equity in connection with the completed merger.
Select Medical Holdings Corp director Katherine R. Davisson disposed of 60,035 shares of common stock at $16.50 per share in connection with a merger. Under the merger agreement, each of her shares, including previously unvested restricted shares that vested immediately before closing, was converted into the right to receive cash, leaving her with no remaining shares.
Select Medical Holdings director William H. Frist disposed of 306,266 shares of common stock in connection with the company’s merger. Each share was converted into the right to receive $16.50 in cash, and his direct common stock holdings fell to zero shares.
The transaction also covered unvested restricted shares, which fully vested immediately before the merger and were converted into the same cash consideration, subject to tax withholding.
SELECT MEDICAL HOLDINGS CORP director Marilyn B. Tavenner disposed of 36,035 shares of common stock in connection with a cash merger. Each share, including previously unvested restricted shares that vested immediately before closing, was converted into the right to receive $16.50 in cash. Following this merger-related conversion, she holds no shares directly.
Select Medical Holdings Corp director Thomas Daniel disposed of his remaining common stock in connection with the company’s merger. On the merger’s effective date, 80,035 shares of common stock were surrendered to the issuer at $16.50 per share, leaving him with no shares reported after the transaction.
Under the Agreement and Plan of Merger, each of his outstanding shares, including previously unvested restricted shares that fully vested immediately before closing, was converted into the right to receive cash merger consideration of $16.50 per share, less applicable tax withholdings.
Khanuja Parvinderjit S. reported disposition transactions in this Form 4 filing.
SELECT MEDICAL HOLDINGS CORP director Parvinderjit S. Khanuja had all of his common shares cashed out in a merger-related transaction. A total of 79,124 shares of common stock, including previously unvested restricted shares, were converted into the right to receive $16.50 per share in cash at the merger effective time, leaving him with no remaining shares.
Select Medical Holdings Corp director James S. Ely III disposed of 161,674 shares of common stock in connection with the company’s merger. At the effective time of the merger, each share, including previously unvested restricted shares, was converted into the right to receive $16.50 in cash per share, leaving him with no remaining shares.
Select Medical Holdings Corp executive vice president John F. Duggan reported a restructuring of 194,710 shares of common stock linked to a merger. The Form 4 shows his direct holdings in issuer common stock fell to 0 shares after the transaction.
Footnotes explain that immediately prior to the merger’s effective time, he contributed 78,043 common shares and 116,667 restricted shares to Stallion Intermediate Corporation in exchange for equivalent Parent Common Shares and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. This reflects a merger-related equity rollover rather than an open-market trade.
Select Medical Holdings executive John Tyler Hollenbach reported a merger-related restructuring of 135,084 common shares. The Form 4 notes these securities were disposed of under an Agreement and Plan of Merger involving Select Medical, Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, Hollenbach contributed 31,751 common shares and 103,333 restricted shares to Stallion Intermediate Corporation. In return, he received an equivalent amount of Parent common and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. Following this restructuring, the Form 4 shows zero Select Medical common shares held directly in this reporting line.